// IP Marketing video - START// IP Marketing video - END

Breakthrough in gene editing could treat ALS, Huntington's disease

Breakthrough in gene editing could treat ALS, Huntington's disease

PanARMENIAN.Net - The most common gene editing technique, CRISPR-Cas9, only modifies DNA. That's helpful in most cases, but it means that you can't use it to tackle RNA-based diseases. Thankfully, that might not be a problem for much longer. After plenty of talk about editing RNA, researchers have developed a new RNA-oriented technique (RCas9) that can correct the molecular errors which lead to diseases like hereditary ALS and Huntington's, Engadget reports.

The team achieved its feat using guide RNA that steers the editing enzyme toward a matching sequence of target RNA molecules. In the lab, it's highly effective -- it fixed nearly all of the broken RNA targets in muscle cells, leaving cells that were far healthier.

Of course, this is in lab conditions. The scientists readily admit that there's much more work to be done before gene editing could help in the field. More than anything, it would be difficult to send RCas9 to patient cells. The benign viruses you'd normally use for gene therapy just can't hold a full-fledged Cas9 payload; the researchers had to prune theirs to make it fit. And of course, there's the question of conducting trials and proving that the technique is safe.

Right now, there aren't any therapies that would stall the onset of diseases like ALS. This wouldn't likely represent a cure, but it could give patients full functionality for longer before the effects of their diseases set in.

 Top stories
T “sleep box” is a wooden box that sits on the bedside table and emits a soft light between the hours of 6 a.m. and 7 a.m.
The suit focuses on 19 PicsArt filters that were supposedly “reverse engineered from VSCO’s filters.”
CEO & Co-Founder of SoloLearn Yeva Hyusyan has made it to the list of 50 female entrepreneurs to watch in 2019.
Nearly 80 percent of PicsArt’s users are under the age of 35 and those under 18 are driving most of its growth.
Partner news